Business · 18/07/1997Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for GLYSET Patent Extension
Summary
The Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of GLYSET, a human drug product, as required by law after receiving a submission from the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →